

Carasent ASA – incentive program for chairman and CEO to be replaced by investments in Carasent SWE shares

Reference is made to Carasent ASA's ("Carasent" or the "Company") stock exchange and press release 30 August 2024 regarding the merger plan for a cross-border merger to the effect that shareholders will have their Carasent shares one for one exchanged with Carasent SWE shares listed only on Nasdaq Stockholm (the "Relisting"). Further reference is made to the Company's stock exchange and press release 3 October 2022 regarding sale of warrants under stock option program with terms of four (50% of the options) and five (50% of the options) years to the chairman of the board of directors for NOK 800,000 and for the CEO for NOK 800,000.

Warrants in Carasent ASA cannot be continued in their current form after the cross-border merger. The Company has agreed with each of the chairman and the CEO that the warrants sold each of them by the Company in 2022 will be cancelled, subject to, and, immediately prior to, the consummation of the cross-border merger and Relisting. The Company will refund the purchase prices they paid. The chairman and the CEO will use the amounts to be refunded in open-market purchases of Carasent SWE shares. Carasent SWE will succeed to Carasent's rights to enforce the agreement pursuant to the merger plan for the cross-border merger.

The cross-border merger remains subject to approval by the Company's shareholders at the extraordinary general meeting to be held on 4 October 2024 and to other conditions precedent, inter alia, obtaining relevant approvals from Nasdaq Stockholm and relevant governmental authorities.

For further information, please contact

Svein Martin Bjørnstad, CFO Tel: +47 979 69 493